tert-Butyl 4-(1H-pyrrolo[3,2-b]pyridin-6-yl)piperazine-1-carboxylate

Catalog No. :
ACNGRK243
CAS No. :
1015609-59-2
Molecular Formula :
C16H22N4O2
Molecular Weight :
302.38

IUPAC Name:tert-butyl 4-(1H-pyrrolo[3,2-b]pyridin-6-yl)piperazine-1-carboxylate

tert-Butyl 4-(1H-pyrrolo[3,2-b]pyridin-6-yl)piperazine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$492.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 4-(1H-pyrrolo[3,2-b]pyridin-6-yl)piperazine-1-carboxylate
IUPAC Nametert-butyl 4-(1H-pyrrolo[3,2-b]pyridin-6-yl)piperazine-1-carboxylate
MDL No.MFCD09859117
Molecular FormulaC16H22N4O2
Molecular Weight302.38
SMILESO=C(N1CCN(C2=CN=C3C(NC=C3)=C2)CC1)OC(C)(C)C
InChI KeyIYRPLSBYGVIJGG-UHFFFAOYSA-N
Synonym1015609-59-2 | MFCD09859117 | tert-Butyl 4-(1H-pyrrolo[3,2-b]pyridin-6-yl)-piperazine-1-carboxylate | tert-Butyl 4-(1H-pyrrolo[3,2-b]pyridin-6-yl)piperazine-1-carboxylate | FT-0739879 | DTXSID90640156 | CS-0335717 | 1-Piperazinecarboxylic acid, 4-(1H-pyrr
CAS No.1015609-59-2
PubChem CID24229267

Safety Data

Pictogram
Toxic
Signal Word
Gefahr
Hazard Statement(s)
H301
Precautionary Statement(s)
P301+P310

Synthetic Route by SureRoute

1. ACNGRK243 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACSMBY023 route compound structure diagram
    ACSMBY023944937-53-5 In Stock
  2. Plus
  3. ACBRWP053 route compound structure diagram
    ACBRWP05357260-72-7 In Stock
  4. Then
  5. ACNGRK243 route product structure diagram
    ACNGRK2431015609-59-2
Inquiry

2. ACNGRK243 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACNGRK243 route product structure diagram
    ACNGRK2431015609-59-2
Inquiry

Comments (0)